The global atopic dermatitis market size was US$ 9.2 billion in 2021. The global atopic dermatitis market size is forecast to reach US$ 21.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.9% during the forecast period from 2022 to 2030.
Atopic Dermatitis is a type of eczema that causes super sensitive skin and a lower threshold for irritation. In addition, it misleads the immune system and contributes to chronic diseases. Atopic dermatitis is prevalent throughout the world, especially in infants and children. People with atopic dermatitis may suffer from hay fever, food allergies, allergic asthma, and anaphylactic shock. Atopic dermatitis can occur in different parts of the body depending on the patient's age, such as knees, inside elbows, wrists, sides of the neck, ankles, and hands, and also develop papules that lead to a rash.
Factors Influencing Market Growth
Impact Analysis of COVID-19
In the world, Atopic Eczema affects up to 24 % of the population, causing skin-related impairments. Nurses who wear protective gloves regularly and regularly wash their hands are at risk of occupational dermatitis, affecting 23 % of them. As a result of the COVID-19 pandemic, everyone was regularly handwashing and wearing protective gloves. Health care workers routinely wash their hands, use personal protective equipment, wear gloves, and suffer chronic stress to prevent the coronavirus causing severe acute respiratory syndrome from spreading, resulting in several lives saved. Despite being protected from COVID-19, they still suffer from dermatitis. Due to low immunity, people with dermatitis symptoms such as skin irritations, allergies, fevers, and more anxiety and depression are also more susceptible to COVID-19. As a result, the COVID-19 pandemic increases the growth of the atopic dermatitis market.
Regional Insights
The North America region dominates the global atopic dermatitis market. Due to well-developed technology, increasing investment in healthcare, an increasing number of patients with reduced fibrillin protein levels, and an increase in government support for research and development. In addition to these factors, greater R & D activities and the concentration of major companies are propelling the market for atopic dermatitis.
Leading Competitors
The leading prominent companies profiled in the global atopic dermatitis market are:
Scope of the Report
The global atopic dermatitis market segmentation focuses on Type, Application, End-User, and Region.
Segmentation based on Type
Segmentation based on Application
Segmentation based on End-User
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ATOPIC DERMATITIS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL ATOPIC DERMATITIS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL ATOPIC DERMATITIS MARKET, BY TYPE
5.1 OVERVIEW
5.2 HORMONE
5.3 ERYTHROPOIETIN
5.4 MONOCLONAL ANTIBODIES
5.5 INTERFERON
5.6 CALCITONIN
5.7 OTHERS
6 GLOBAL ATOPIC DERMATITIS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 CANCER
6.3 BLOOD DISORDERS
6.4 CHRONIC DISEASES
6.5 INFECTIOUS DISEASES
6.6 OTHERS
7 GLOBAL ATOPIC DERMATITIS MARKET, BY END-USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 CLINICS
7.4 RESEARCH CENTERS
8 GLOBAL ATOPIC DERMATITIS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL ATOPIC DERMATITIS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 ASTELLAS PHARMA INCORPORATED
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 SANOFI S.A.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 REGENERON PHARMACEUTICALS, INCORPORATED
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 VALEANT PHARMACEUTICALS INTERNATIONAL, INCORPORATED
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 ANACOR PHARMACEUTICALS INCORPORATED
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 NOVARTIS INTERNATIONAL AG
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 BRISTOL-MYERS SQUIBB
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8 MEDA PHARMACEUTICALS
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 PFIZER INCORPORATED
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 GALDERMA S.A.
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.11 ALLERGAN PLC.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved